GlassScriptPhysician profile
James J Swetech
NPI 1336189232
$52,734.68
in general payments reported to CMS, 2019-2025
35 companies · $6,283 in 2025
The $6,283 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $7,036 · 2021: $5,652 · 2022: $8,182 · 2023: $4,366 · 2024: $1,971 · 2025: $6,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,293 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,850 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,400 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,292.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,850.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,400.00 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33,453.07 | 2019-2025 | Trulance, Xifaxan |
| Romark Laboratories, Lc | $4,397.63 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $2,657.29 | 2024-2025 | Iqirvo |
| Janssen Pharmaceuticals, INC | $2,120.10 | 2019-2024 | Invega Trinza, Invega Sustenna |
| Abbvie INC. | $1,839.25 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Madrigal Pharmaceuticals | $1,026.68 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $884.91 | 2019-2025 | Livdelzi, Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $864.31 | 2019-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $688.82 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $654.40 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Medtronic, INC. | $501.07 | 2022-2025 | Gi Genius, Interstim |
| Intercept Pharmaceuticals, INC. | $472.82 | 2019-2024 | Ocaliva |
| Allergan, INC. | $432.33 | 2019-2020 | |
| Ambu INC. | $334.68 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $287.76 | 2024-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $178.36 | 2022-2024 | Omvoh |
| Daiichi Sankyo INC. | $163.34 | 2019-2025 | Vanflyta |
| Astrazeneca Pharmaceuticals LP | $138.28 | 2025 | Wainua |
| Erbe USA INC | $135.85 | 2022 | |
| Janssen Scientific Affairs, LLC | $131.70 | 2025 | Tremfya |
| Qol Medical, LLC | $130.84 | 2024 | Sucraid |
| Genzyme Corporation | $125.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Olympus America INC. | $124.53 | 2022 | |
| Pentax of America, INC. | $117.68 | 2022 | |
| Aimmune Therapeutics, INC. | $116.61 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $114.03 | 2025 | Wegovy |
| Celgene Corporation | $89.63 | 2021-2023 | Zeposia |
| Merit Medical Systems INC | $86.00 | 2022 | |
| Capsovision, INC. | $80.30 | 2023-2024 | Capsocam Plus |
| Cook Medical LLC | $79.33 | 2019 | |
| Eisai INC. | $75.09 | 2022 | |
| Shionogi INC | $49.98 | 2019-2020 | |
| Pfizer INC. | $33.46 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $24.55 | 2022-2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Swetech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.